Jianjun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianjun Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Fangming Li
Department of Neurology Shenzhen University, Shenzhen University General Hospital Shenzhen China
1 shared publication- Jianyang Dong
Rehabilitation Medicine Department, Neuroscience Cluster, The Fourth People's Hospital of Shenzhen, Shenzhen, China
1 shared publication Mengying Dai
Department of Rehabilitation Shenzhen Children's Hospital Shenzhen China
1 shared publicationTing Xu
Department of Neurology, Guangzhou First People's Hospital South China University of Technology Guangzhou China
1 shared publicationZinan Guo
Department of Rehabilitation Shenzhen University, Shenzhen University General Hospital Shenzhen China
1 shared publication
Latest Publications
- Open Access
- 5 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70505
The Targets of Deep Brain Stimulation in the Treatment of Treatment‐Resistant Depression: A Review
Purpose: The purpose of this review is to evaluate the current state and potential future directions of deep brain stimulation (DBS) therapy for treatment‐resistant depression (TRD), a condition that significantly impacts patients' quality of life and for which conventional treatments are often ineffective.Method: This review synthesizes evidence from clinical trials and preclinical studies published in five years, identified through PubMed searches using keywords (“Deep Brain Stimulation” OR DBS) AND (“Treatment‐Resistant Depression” OR TRD). Included studies encompassed clinical research (randomized/non‐randomized trials, cohort studies) and mechanistic preclinical studies, excluding non‐English publications and nonhuman experiments. Screening prioritized neuroanatomical targets (e.g., SCG, NAcc) and stimulation parameter optimization data. Examining the therapeutic mechanisms of DBS, the neuroanatomical targets utilized, and the clinical outcomes observed. It also discusses the challenges faced in DBS application and proposes potential technological advancements, such as closed‐loop therapy and fiber tracking technology.Finding: Preliminary evidence exists regarding the efficacy and safety of DBS in the treatment of TRD in the subcortical cingulate gyrus (SCG), nucleus accumbens (NAcc), ventral capsule/ventral striatum (VC/VS), anterior limb of the internal capsule (ALIC), and so forth. Nevertheless, the optimal stimulation target remains undetermined. The review highlights the complexity of TRD and the need for personalized treatment strategies, noting that genetic, epigenetic, and neurophysiological changes are implicated in DBS's therapeutic effects.Conclusion: In conclusion, while DBS for TRD remains an experimental therapy, it offers a unique and potentially effective treatment option for patients unresponsive to traditional treatments. The review emphasizes the need for further research to refine DBS targets and parameters, improve patient selection, and develop personalized treatment plans to enhance efficacy and safety in TRD management.
- 5 May 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (5) , e70505
Open AccessThe Targets of Deep Brain Stimulation in the Treatment of Treatment‐Resistant Depression: A Review
Purpose: The purpose of this review is to evaluate the current state and potential future directions of deep brain stimulation (DBS) therapy for treatment‐resistant depression (TRD), a condition that significantly impacts patients' quality of life and for which conventional treatments are often ineffective.Method: This review synthesizes evidence from clinical trials and preclinical studies published in five years, identified through PubMed searches using keywords (“Deep Brain Stimulation” OR DBS) AND (“Treatment‐Resistant Depression” OR TRD). Included studies encompassed clinical research (randomized/non‐randomized trials, cohort studies) and mechanistic preclinical studies, excluding non‐English publications and nonhuman experiments. Screening prioritized neuroanatomical targets (e.g., SCG, NAcc) and stimulation parameter optimization data. Examining the therapeutic mechanisms of DBS, the neuroanatomical targets utilized, and the clinical outcomes observed. It also discusses the challenges faced in DBS application and proposes potential technological advancements, such as closed‐loop therapy and fiber tracking technology.Finding: Preliminary evidence exists regarding the efficacy and safety of DBS in the treatment of TRD in the subcortical cingulate gyrus (SCG), nucleus accumbens (NAcc), ventral capsule/ventral striatum (VC/VS), anterior limb of the internal capsule (ALIC), and so forth. Nevertheless, the optimal stimulation target remains undetermined. The review highlights the complexity of TRD and the need for personalized treatment strategies, noting that genetic, epigenetic, and neurophysiological changes are implicated in DBS's therapeutic effects.Conclusion: In conclusion, while DBS for TRD remains an experimental therapy, it offers a unique and potentially effective treatment option for patients unresponsive to traditional treatments. The review emphasizes the need for further research to refine DBS targets and parameters, improve patient selection, and develop personalized treatment plans to enhance efficacy and safety in TRD management.